Abstract
The sirtuins are protein modifying enzymes widely distributed in all forms of life. The sirtuins are principally NAD+-dependent protein acetyl-lysine deacetylases that reverse acetyl-modifications of proteins. The sirtuins are implicated in a variety of adaptations to reduced nutritional intake, and increase lifespan in several model organisms, such as yeast, flies and worms. The human sirtuins (SIRT1-7) have been identified to regulate a variety of biological processes, such as glucose homeostasis, gluconeogenesis, mitochondrial biogenesis, insulin secretion, adipogenesis and adipolysis, apoptosis, senescence and metabolism. The potency of sirtuins in regulating mammalian biological processes invites consideration of them as potential drug targets. This review considers small molecule approaches to activate sirtuins in a biochemical and biological context. These approaches include allosteric activation, which has been demonstrated for the SIRT1 enzyme. Another approach discussed is enhancement of NAD+ levels in cells, since sirtuins appear to be responsive to increased cellular NAD+. Finally, a sirtuin-specific approach is considered that is called nicotinamide derepression. This approach is designed to antagonize physiologic nicotinamide inhibition of sirtuins as a means to upregulate sirtuin function. Biological data that provides evidence of effectiveness of these approaches in in vitro and in vivo contexts is presented along with a discussion of the theoretical considerations that underpin these strategies. Efficacies and shortcomings of the various approaches are also discussed.
Keywords: Sir2, Sirtuins, Resveratrol, isonicotinamide, nicotinamide riboside, NAD, caloric restriction, enzyme activatio
Current Pharmaceutical Design
Title: Pharmaceutical Strategies for Activating Sirtuins
Volume: 15 Issue: 1
Author(s): Anthony A. Sauve
Affiliation:
Keywords: Sir2, Sirtuins, Resveratrol, isonicotinamide, nicotinamide riboside, NAD, caloric restriction, enzyme activatio
Abstract: The sirtuins are protein modifying enzymes widely distributed in all forms of life. The sirtuins are principally NAD+-dependent protein acetyl-lysine deacetylases that reverse acetyl-modifications of proteins. The sirtuins are implicated in a variety of adaptations to reduced nutritional intake, and increase lifespan in several model organisms, such as yeast, flies and worms. The human sirtuins (SIRT1-7) have been identified to regulate a variety of biological processes, such as glucose homeostasis, gluconeogenesis, mitochondrial biogenesis, insulin secretion, adipogenesis and adipolysis, apoptosis, senescence and metabolism. The potency of sirtuins in regulating mammalian biological processes invites consideration of them as potential drug targets. This review considers small molecule approaches to activate sirtuins in a biochemical and biological context. These approaches include allosteric activation, which has been demonstrated for the SIRT1 enzyme. Another approach discussed is enhancement of NAD+ levels in cells, since sirtuins appear to be responsive to increased cellular NAD+. Finally, a sirtuin-specific approach is considered that is called nicotinamide derepression. This approach is designed to antagonize physiologic nicotinamide inhibition of sirtuins as a means to upregulate sirtuin function. Biological data that provides evidence of effectiveness of these approaches in in vitro and in vivo contexts is presented along with a discussion of the theoretical considerations that underpin these strategies. Efficacies and shortcomings of the various approaches are also discussed.
Export Options
About this article
Cite this article as:
Sauve A. Anthony, Pharmaceutical Strategies for Activating Sirtuins, Current Pharmaceutical Design 2009; 15 (1) . https://dx.doi.org/10.2174/138161209787185797
DOI https://dx.doi.org/10.2174/138161209787185797 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry Evaluation of Neuroprotective effect of <i>Cassia occidentalis L</i>. against Colchicine Induced Memory Impairment in Wistar Rats
Current Nutraceuticals Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Neurotoxicity of Insecticides
Current Medicinal Chemistry Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Rationally Designed Multi-Targeted Agents Against Neurodegenerative Diseases
Current Medicinal Chemistry The Anterior-posterior Functional Connectivity Disconnection in the Elderly with Subjective Memory Impairment and Amnestic Mild Cognitive Impairment
Current Alzheimer Research Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Development of a Non Invasive NGF-Based Therapy for Alzheimers Disease
Current Alzheimer Research Meet Our Associate Editor
Central Nervous System Agents in Medicinal Chemistry Clonal Expansion of Mitochondrial DNA Deletions and the Progression of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Multi-Target-Directed Ligands in Alzheimer's Disease Treatment
Current Medicinal Chemistry The Complement Cascade: New Avenues in Stroke Therapy
Current Vascular Pharmacology Effect of Simvastatin on Inflammatory Cytokines Balance in Air Pouch Granuloma Model
Inflammation & Allergy - Drug Targets (Discontinued) Meet Our Editorial Board Member
Current Aging Science Human PON Promoters: From Similarity to Prediction of Polymorphic Positions within Transcription Factor Elements
Mini-Reviews in Medicinal Chemistry The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents
CNS & Neurological Disorders - Drug Targets Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Insulin Resistance in Alzheimer Disease: p53 and MicroRNAs as Important Players
Current Topics in Medicinal Chemistry Diabetes Mellitus to Neurodegenerative Disorders: Is Oxidative Stress Fueling the Flame?
CNS & Neurological Disorders - Drug Targets